$APYX
Apyx Medical Corp

2024 Q4 Form 10-Q Financial Statement

#000143774924034193 Filed on November 08, 2024

View on sec.gov

Income Statement

Concept 2024 Q4 2024 Q3
Revenue $11.49M
YoY Change -4.08%
Cost Of Revenue $4.533M
YoY Change 13.38%
Gross Profit $6.954M
YoY Change -12.84%
Gross Profit Margin 60.54%
Selling, General & Admin $4.291M
YoY Change -11.36%
% of Gross Profit 61.71%
Research & Development $1.142M
YoY Change -10.5%
% of Gross Profit 16.42%
Depreciation & Amortization $144.0K
YoY Change -24.21%
% of Gross Profit 2.07%
Operating Expenses $10.59M
YoY Change -16.06%
Operating Profit -$3.635M
YoY Change -21.61%
Interest Expense -$1.053M
YoY Change -280.0%
% of Operating Profit
Other Income/Expense, Net -$1.029M
YoY Change 189.04%
Pretax Income -$4.664M
YoY Change -6.59%
Income Tax $60.00K
% Of Pretax Income
Net Earnings -$4.703M
YoY Change 1.6%
Net Earnings / Revenue -40.94%
Basic Earnings Per Share -$0.14
Diluted Earnings Per Share -$0.14
COMMON SHARES
Basic Shares Outstanding 34.64M 34.64M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2024 Q4 2024 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $28.01M
YoY Change 26.76%
Cash & Equivalents $28.01M
Short-Term Investments
Other Short-Term Assets $2.109M
YoY Change -39.74%
Inventory $9.000M
Prepaid Expenses
Receivables $13.04M
Other Receivables $0.00
Total Short-Term Assets $52.16M
YoY Change 4.0%
LONG-TERM ASSETS
Property, Plant & Equipment $1.905M
YoY Change -8.98%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $1.785M
YoY Change -3.77%
Total Long-Term Assets $8.563M
YoY Change -7.89%
TOTAL ASSETS
Total Short-Term Assets $52.16M
Total Long-Term Assets $8.563M
Total Assets $60.72M
YoY Change 2.14%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.914M
YoY Change -6.63%
Accrued Expenses $7.291M
YoY Change -2.79%
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due $20.00K
YoY Change
Total Short-Term Liabilities $9.555M
YoY Change -7.18%
LONG-TERM LIABILITIES
Long-Term Debt $33.85M
YoY Change 275.77%
Other Long-Term Liabilities $201.0K
YoY Change 11.05%
Total Long-Term Liabilities $34.05M
YoY Change 270.55%
TOTAL LIABILITIES
Total Short-Term Liabilities $9.555M
Total Long-Term Liabilities $34.05M
Total Liabilities $49.52M
YoY Change 91.51%
SHAREHOLDERS EQUITY
Retained Earnings -$73.28M
YoY Change 63.43%
Common Stock $35.00K
YoY Change 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $11.04M
YoY Change
Total Liabilities & Shareholders Equity $60.72M
YoY Change 2.14%

Cashflow Statement

Concept 2024 Q4 2024 Q3
OPERATING ACTIVITIES
Net Income -$4.703M
YoY Change 1.6%
Depreciation, Depletion And Amortization $144.0K
YoY Change -24.21%
Cash From Operating Activities -$4.440M
YoY Change -220.33%
INVESTING ACTIVITIES
Capital Expenditures $153.0K
YoY Change -10.0%
Acquisitions
YoY Change
Other Investing Activities $0.00
YoY Change
Cash From Investing Activities -$153.0K
YoY Change -10.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -5.000K
YoY Change -103.13%
NET CHANGE
Cash From Operating Activities -4.440M
Cash From Investing Activities -153.0K
Cash From Financing Activities -5.000K
Net Change In Cash -4.598M
YoY Change -224.95%
FREE CASH FLOW
Cash From Operating Activities -$4.440M
Capital Expenditures $153.0K
Free Cash Flow -$4.593M
YoY Change -230.48%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Central Index Key
EntityCentralIndexKey
0000719135
dei Entity Registrant Name
EntityRegistrantName
Apyx Medical Corp
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
CY2024Q3 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
750000 usd
CY2023Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
608000 usd
CY2024Q3 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
930000 usd
CY2023Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
875000 usd
CY2024Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
3889000 usd
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
3522000 usd
CY2024Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2024Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2024Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2024Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
75000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
75000000
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
34643926
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
34643926
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
34643888
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
34643888
CY2024Q3 apyx Board Of Directors Annual Cash Compensation Liability
BoardOfDirectorsAnnualCashCompensationLiability
500000 usd
us-gaap Debt Instrument Variable Interest Rate Type Extensible Enumeration
DebtInstrumentVariableInterestRateTypeExtensibleEnumeration
http://fasb.org/us-gaap/2024#SecuredOvernightFinancingRateSofrMember
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
2 pure
CY2024Q3 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-31885
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
11-2644611
dei Entity Address Address Line1
EntityAddressAddressLine1
5115 Ulmerton Road
dei Entity Address City Or Town
EntityAddressCityOrTown
Clearwater
dei Entity Address State Or Province
EntityAddressStateOrProvince
FL
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
33760
dei City Area Code
CityAreaCode
727
dei Local Phone Number
LocalPhoneNumber
384-2323
dei Security12b Title
Security12bTitle
Common Stock
dei Trading Symbol
TradingSymbol
APYX
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
34643886
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
28013000 usd
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
43652000 usd
CY2024Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
13036000 usd
CY2023Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
14023000 usd
CY2024Q3 us-gaap Inventory Net
InventoryNet
9000000 usd
CY2023Q4 us-gaap Inventory Net
InventoryNet
9923000 usd
CY2024Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2109000 usd
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2764000 usd
CY2024Q3 us-gaap Assets Current
AssetsCurrent
52158000 usd
CY2023Q4 us-gaap Assets Current
AssetsCurrent
70362000 usd
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1905000 usd
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1915000 usd
CY2024Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
4820000 usd
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
5162000 usd
CY2024Q3 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
53000 usd
CY2023Q4 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
69000 usd
CY2024Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1785000 usd
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1732000 usd
CY2024Q3 us-gaap Assets
Assets
60721000 usd
CY2023Q4 us-gaap Assets
Assets
79240000 usd
CY2024Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
1914000 usd
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2712000 usd
CY2024Q3 apyx Accrued Liabilities And Other Liabilities Current
AccruedLiabilitiesAndOtherLiabilitiesCurrent
7291000 usd
CY2023Q4 apyx Accrued Liabilities And Other Liabilities Current
AccruedLiabilitiesAndOtherLiabilitiesCurrent
9661000 usd
CY2024Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
330000 usd
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
347000 usd
CY2024Q3 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
20000 usd
CY2023Q4 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
20000 usd
CY2024Q3 us-gaap Liabilities Current
LiabilitiesCurrent
9555000 usd
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
12740000 usd
CY2024Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
33853000 usd
CY2023Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
33185000 usd
CY2024Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
4606000 usd
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
4896000 usd
CY2024Q3 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
38000 usd
CY2023Q4 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
53000 usd
CY2024Q3 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
1271000 usd
CY2023Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
1246000 usd
CY2024Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
201000 usd
CY2023Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
198000 usd
CY2024Q3 us-gaap Liabilities
Liabilities
49524000 usd
CY2023Q4 us-gaap Liabilities
Liabilities
52318000 usd
CY2024Q3 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2024Q3 us-gaap Common Stock Value
CommonStockValue
35000 usd
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
35000 usd
CY2024Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
84289000 usd
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
81114000 usd
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-73283000 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-54448000 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
11041000 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
26701000 usd
CY2024Q3 us-gaap Minority Interest
MinorityInterest
156000 usd
CY2023Q4 us-gaap Minority Interest
MinorityInterest
221000 usd
CY2024Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
11197000 usd
CY2023Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
26922000 usd
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
60721000 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
79240000 usd
CY2024Q3 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
11487000 usd
CY2023Q3 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
11976000 usd
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
33880000 usd
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
37687000 usd
CY2024Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
4533000 usd
CY2023Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
3998000 usd
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
13484000 usd
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
12857000 usd
CY2024Q3 us-gaap Gross Profit
GrossProfit
6954000 usd
CY2023Q3 us-gaap Gross Profit
GrossProfit
7978000 usd
us-gaap Gross Profit
GrossProfit
20396000 usd
us-gaap Gross Profit
GrossProfit
24830000 usd
CY2024Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1142000 usd
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1409000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3963000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4037000 usd
CY2024Q3 us-gaap Professional Fees
ProfessionalFees
1648000 usd
CY2023Q3 us-gaap Professional Fees
ProfessionalFees
1831000 usd
us-gaap Professional Fees
ProfessionalFees
5318000 usd
us-gaap Professional Fees
ProfessionalFees
5165000 usd
CY2024Q3 us-gaap Labor And Related Expense
LaborAndRelatedExpense
3508000 usd
CY2023Q3 us-gaap Labor And Related Expense
LaborAndRelatedExpense
4534000 usd
us-gaap Labor And Related Expense
LaborAndRelatedExpense
12886000 usd
us-gaap Labor And Related Expense
LaborAndRelatedExpense
14329000 usd
CY2024Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
4291000 usd
CY2023Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
4841000 usd
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
14026000 usd
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
15474000 usd
CY2024Q3 us-gaap Operating Expenses
OperatingExpenses
10589000 usd
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
12615000 usd
us-gaap Operating Expenses
OperatingExpenses
36193000 usd
us-gaap Operating Expenses
OperatingExpenses
39005000 usd
CY2024Q3 us-gaap Sale And Leaseback Transaction Gain Loss Net
SaleAndLeasebackTransactionGainLossNet
0 usd
CY2023Q3 us-gaap Sale And Leaseback Transaction Gain Loss Net
SaleAndLeasebackTransactionGainLossNet
0 usd
us-gaap Sale And Leaseback Transaction Gain Loss Net
SaleAndLeasebackTransactionGainLossNet
0 usd
us-gaap Sale And Leaseback Transaction Gain Loss Net
SaleAndLeasebackTransactionGainLossNet
2692000 usd
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-3635000 usd
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-4637000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-15797000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-11483000 usd
CY2024Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
378000 usd
CY2023Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
248000 usd
us-gaap Investment Income Interest
InvestmentIncomeInterest
1312000 usd
us-gaap Investment Income Interest
InvestmentIncomeInterest
478000 usd
CY2024Q3 us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
1431000 usd
CY2023Q3 us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
585000 usd
us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
4254000 usd
us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
1362000 usd
CY2024Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
24000 usd
CY2023Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-19000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
2000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
622000 usd
CY2024Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1029000 usd
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-356000 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-2940000 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-262000 usd
CY2024Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-4664000 usd
CY2023Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-4993000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-18737000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-11745000 usd
CY2024Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
60000 usd
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-318000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
163000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-2519000 usd
CY2024Q3 us-gaap Profit Loss
ProfitLoss
-4724000 usd
CY2023Q3 us-gaap Profit Loss
ProfitLoss
-4675000 usd
us-gaap Profit Loss
ProfitLoss
-18900000 usd
us-gaap Profit Loss
ProfitLoss
-9226000 usd
CY2024Q3 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-21000 usd
CY2023Q3 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-46000 usd
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-65000 usd
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-120000 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-4703000 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-4629000 usd
us-gaap Net Income Loss
NetIncomeLoss
-18835000 usd
us-gaap Net Income Loss
NetIncomeLoss
-9106000 usd
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.14
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.13
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.54
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.26
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
37793000 usd
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1367000 usd
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
586000 usd
CY2023Q1 us-gaap Profit Loss
ProfitLoss
-3532000 usd
CY2023Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
36214000 usd
CY2023Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
56000 usd
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1482000 usd
CY2023Q2 us-gaap Profit Loss
ProfitLoss
-1019000 usd
CY2023Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
36733000 usd
CY2023Q3 us-gaap Noncontrolling Interest Increase From Subsidiary Equity Issuance
NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance
147000 usd
CY2023Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
30000 usd
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1351000 usd
CY2023Q3 us-gaap Profit Loss
ProfitLoss
-4675000 usd
CY2023Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
33586000 usd
CY2023Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
26922000 usd
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1128000 usd
CY2024Q1 us-gaap Profit Loss
ProfitLoss
-7590000 usd
CY2024Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
20460000 usd
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1050000 usd
CY2024Q2 us-gaap Profit Loss
ProfitLoss
-6586000 usd
CY2024Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
14924000 usd
CY2024Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
997000 usd
CY2024Q3 us-gaap Profit Loss
ProfitLoss
-4724000 usd
CY2024Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
11197000 usd
us-gaap Profit Loss
ProfitLoss
-18900000 usd
us-gaap Profit Loss
ProfitLoss
-9226000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
457000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
540000 usd
us-gaap Inventory Write Down
InventoryWriteDown
61000 usd
us-gaap Inventory Write Down
InventoryWriteDown
229000 usd
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-48000 usd
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
2656000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
3175000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
4200000 usd
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
146000 usd
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
176000 usd
apyx Noncash Lease Expense
NoncashLeaseExpense
86000 usd
apyx Noncash Lease Expense
NoncashLeaseExpense
56000 usd
us-gaap Paid In Kind Interest
PaidInKindInterest
668000 usd
us-gaap Paid In Kind Interest
PaidInKindInterest
354000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-879000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
2192000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-542000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
698000 usd
us-gaap Increase Decrease In Income Taxes Receivable
IncreaseDecreaseInIncomeTaxesReceivable
-0 usd
us-gaap Increase Decrease In Income Taxes Receivable
IncreaseDecreaseInIncomeTaxesReceivable
-7545000 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-902000 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-401000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-819000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-613000 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-2355000 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-1153000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-15110000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3037000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
477000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
440000 usd
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
0 usd
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
7267000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-477000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
6827000 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
0 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
86000 usd
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
0 usd
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
9289000 usd
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
-0 usd
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
1754000 usd
us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
0 usd
us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
586000 usd
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
15000 usd
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
32000 usd
us-gaap Proceeds From Minority Shareholders
ProceedsFromMinorityShareholders
0 usd
us-gaap Proceeds From Minority Shareholders
ProceedsFromMinorityShareholders
147000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-15000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
8322000 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-37000 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-170000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-15639000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
11942000 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
43652000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
10192000 usd
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
28013000 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
22134000 usd
us-gaap Interest Paid Net
InterestPaidNet
3579000 usd
us-gaap Interest Paid Net
InterestPaidNet
834000 usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
211000 usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
261000 usd
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0 usd
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
4917000 usd
CY2024Q3 us-gaap Inventory Raw Materials
InventoryRawMaterials
4078000 usd
CY2023Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
4112000 usd
CY2024Q3 us-gaap Inventory Work In Process
InventoryWorkInProcess
2434000 usd
CY2023Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
2257000 usd
CY2024Q3 us-gaap Inventory Finished Goods
InventoryFinishedGoods
3418000 usd
CY2023Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
4429000 usd
CY2024Q3 us-gaap Inventory Gross
InventoryGross
9930000 usd
CY2023Q4 us-gaap Inventory Gross
InventoryGross
10798000 usd
CY2024Q3 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
930000 usd
CY2023Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
875000 usd
CY2024Q3 us-gaap Inventory Net
InventoryNet
9000000 usd
CY2023Q4 us-gaap Inventory Net
InventoryNet
9923000 usd
CY2024Q3 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
1259000 usd
CY2023Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
829000 usd
CY2024Q3 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
0 usd
CY2023Q4 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
1545000 usd
CY2024Q3 us-gaap Accrued Sales Commission Current
AccruedSalesCommissionCurrent
641000 usd
CY2023Q4 us-gaap Accrued Sales Commission Current
AccruedSalesCommissionCurrent
1489000 usd
CY2024Q3 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
458000 usd
CY2023Q4 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
445000 usd
CY2024Q3 us-gaap Accrued Insurance Current
AccruedInsuranceCurrent
3036000 usd
CY2023Q4 us-gaap Accrued Insurance Current
AccruedInsuranceCurrent
3521000 usd
CY2024Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
485000 usd
CY2023Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
518000 usd
CY2024Q3 apyx Shortterm Contract Liabilities
ShorttermContractLiabilities
499000 usd
CY2023Q4 apyx Shortterm Contract Liabilities
ShorttermContractLiabilities
488000 usd
CY2024Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
913000 usd
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
826000 usd
CY2024Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7291000 usd
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
9661000 usd
CY2024Q3 us-gaap Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year
LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
0 usd
CY2024Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
0 usd
CY2024Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
0 usd
CY2024Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
2216000 usd
CY2024Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
35284000 usd
CY2024Q3 us-gaap Long Term Debt
LongTermDebt
37500000 usd
CY2024Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-4703000 usd
CY2023Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-4629000 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-18835000 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-9106000 usd
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
34644000
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
34642000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
34644000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
34614000
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.14
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.13
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.54
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.26
CY2024Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
997000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3175000 usd
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1351000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4200000 usd
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
7342883
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
6.31
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1587929
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
2.26
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
569
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
2.5
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
673653
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
6.61
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
8256590
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
5.51
CY2024Q3 apyx Stock Issued During Period Shares Stock Swaps
StockIssuedDuringPeriodSharesStockSwaps
0
CY2023Q3 apyx Stock Issued During Period Shares Stock Swaps Equity Instruments Received
StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived
6662
CY2023Q3 apyx Stock Issued During Period Shares Stock Swaps
StockIssuedDuringPeriodSharesStockSwaps
5338
apyx Stock Issued During Period Shares Stock Swaps Equity Instruments Received
StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived
531
apyx Stock Issued During Period Shares Stock Swaps Equity Instruments Received
StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived
10967
apyx Stock Issued During Period Shares Stock Swaps
StockIssuedDuringPeriodSharesStockSwaps
38
apyx Stock Issued During Period Shares Stock Swaps
StockIssuedDuringPeriodSharesStockSwaps
11033
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.039 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.042 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.921 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.951 pure
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
CY2024Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
60000 usd
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-318000 usd
CY2024Q3 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.013 pure
CY2023Q3 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.064 pure
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
163000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-2519000 usd
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.009 pure
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.214 pure
CY2023Q1 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
2100000 usd
CY2024Q3 us-gaap Purchase Obligation
PurchaseObligation
2700000 usd
CY2024Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
11487000 usd
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-3635000 usd
CY2024Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
378000 usd
CY2024Q3 us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
1431000 usd
CY2024Q3 us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
24000 usd
CY2024Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
60000 usd
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
11976000 usd
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-4637000 usd
CY2023Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
248000 usd
CY2023Q3 us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
585000 usd
CY2023Q3 us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
-19000 usd
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-318000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
33880000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-15797000 usd
us-gaap Investment Income Interest
InvestmentIncomeInterest
1312000 usd
us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
4254000 usd
us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
2000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
163000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
37687000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-11483000 usd
us-gaap Investment Income Interest
InvestmentIncomeInterest
478000 usd
us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
1362000 usd
us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
622000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-2519000 usd
CY2024Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
11487000 usd
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
11976000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
33880000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
37687000 usd

Files In Submission

Name View Source Status
0001437749-24-034193-index-headers.html Edgar Link pending
0001437749-24-034193-index.html Edgar Link pending
0001437749-24-034193.txt Edgar Link pending
0001437749-24-034193-xbrl.zip Edgar Link pending
apyx-20240930.xsd Edgar Link pending
apyx20240930_10q.htm Edgar Link pending
ex_717066.htm Edgar Link pending
ex_717067.htm Edgar Link pending
ex_717068.htm Edgar Link pending
ex_717069.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
logo01.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
apyx-20240930_pre.xml Edgar Link unprocessable
apyx-20240930_def.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
apyx20240930_10q_htm.xml Edgar Link completed
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
apyx-20240930_cal.xml Edgar Link unprocessable
apyx-20240930_lab.xml Edgar Link unprocessable